UCB : Financial Reporting Document

Further Facts & Figures

Full-Year Report 2023

28th of February 2024

Disclaimer & safe harbor

This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation or duty to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Proprietary and Confidential Property of UCB

.	2
UCB - FY 2023 Facts & Figures, February 2024

INTRODUCTION

3

Proprietary and Confidential Property of UCB

UCB Story - Since 1928

Continuous adaptation to the changing ecosystem

1928

Emmanuel Janssen established Union

Chimique Belge

(UCB) in Brussels (Belgium), primarily focusing on industrial chemicals

	80's
	Globalization
	with acquisitions in the
Stronger focus on	US, Korea, Thailand
and Japan
research, resulting in the

discovery in 1954 of one of the world's first tranquillizers, Atarax®

2004

Focus on biopharmaceuticals

A combination of large, antibody-based	2022
molecules and small, chemically-
derived molecules		2008
Acquisition of Celltech Group Ltd,	a
leading British biotechnology company	2019
Divestiture of non-core business,
starting with the films and chemical			Through acquisition of
divisions, followed by primary
care products			Zogenix, Inc.

and Confidential Property of UCB

	1970's - Development of	1987
Production primary care	a European network
through acquisitions in
products (calcium,	France, Germany, Italy,
vitamins, insulin, etc.)	Spain and the U.K.
during World War II

2006	2016	2021	2023
2000	Acquisition of Schwarz Pharma AG,
based in Germany, bringing

complementary therapeutic and geographic focus

Proprietary

Note: the timeline is not proportionated.

UCB - FY 2023 Facts & Figures, February 2024

4

UCB Patient Value Strategy

Sustained Company Growth - superior Shareholder Value

Creating Value For Patients

Our ambition is to be the patient-preferred biopharma leader, creating patient value for specific populations through

unique outcomes, the best experience and improving as many of these lives as possible.

Property of UCB

Global biopharmaceutical company with 95+ years of dedication to our stakeholders: people living with severe diseases, employees, communities we live in, the planet, shareholders

>9000 employees world-wide*

Powered by scientific excellence and pioneering research

Key for UCB is innovation - relentless drive to bring innovative medicines. We bring our portfolio of differentiated solutions to people living

with severe diseases

CIMZIA® EVENITY®

VIMPAT® FINTEPLA®

KEPPRA® BIMZELX®

BRIVIACT® RYSTIGGO®

NAYZILAM® ZILBRYSQ®

Proprietary and Confidential

* Data as of 31st of December 2023.

UCB - FY 2023 Facts & Figures, February 2024

5

UCB's Achievements - Innovation

Impressive Successes to date, based on Innovation, enabling Company Growth

UCB's innovative spirit is exemplified by an impressive tally of 10 + 2 positive phase 3 readouts

External recognition as 2nd most innovative pharma company in 20231

R&D productivity, with end-to-end success rates that soar to three times higher than the industry benchmark2

14 approvals in the last 14 months,

across 6 patient populations, across 3 continents

1. clinical-stagepipeline of 10 unique assets addressing well-definedunmet patient needs

Sustainability is our business approach, and we are committed to sustainable growth

2023 FDA Approvals for Major Pharma1

52nd most internally developed NME -

4FDA approvals

in 2023

3

2

1

0

A

UCB

B

C

D

E

F

Success rates lead indications (%, 2013-2022)

UCBIndustry2

End-to-End

23%

7%

3x

Proprietary and Confidential Property of UCB

1 FirstWord PHARMA: Vital Signs: The most innovative pharmas of 2023 - January 14, 2024; 2 2023 CMR Global R&D Program; NME = New Molecular Entities.

UCB - FY 2023 Facts & Figures, February 2024

6

UCB's Portfolio 5 Unique and De-risked Growth Drivers

®

First agent for anti-AChR+ & anti-MuSK+	First-in-classfor Bone Builder

First once-daily C5 inhibitor	Unique and dual mode of action

First and only IL-17A & IL-17Finhibitor1

1 Demonstrated in Psoriasis through speed, depth & durability - Clarivate l DRG, LANDSCAPE & FORECAST, Psoriasis, December 20, 2023;

AChR+ = Acetylcholinesterase Receptor Positive; gMG = generalized Myasthenia Gravis; MUSK+ = Muscle Specific Kinase Positive; nr-axSpA = non-radiographic Axial Spondyloarthritis; IL = interleukin.

UCB - FY 2023 Facts & Figures, February 2024

Proprietary and Confidential Property of UCB

7

UCB's Performance

Past Inflection Point and Started a Decade+ of Growth

2023 FINANCIAL and EXTRA-FINANCIAL

2023 financial guidance delivered

Inflection point at HY: Back to growth since H2

2023: +3% revenue

ESG Industry Top Rated by Sustainalytics

Strong performance of new launches

EVENITY® +140%3

FINTEPLA® +94%

BIMZELX® +323%

RYSTIGGO®

2023 MARKED BY

>3.2 million patients using UCB medicines1, 40% of epilepsy treatments in US + EU (Japan 30%) UCB generated

14 approvals since January 2023

BIMZELX® approved & launched

US: PSO

Europe & Japan: PsA and axSpA >18k patients treated globally

RYSTIGGO® & ZILBRYSQ®

approved & launches ongoing/starting US, Japan & Europe

EVENITY®: worldwide sales of >$1bn2

Q4 2033: Loss of exclusivity date for FINTEPLA®

2024 MARKED BY

Strong growth of EVENITY®, FINTEPLA®, BIMZELX®, RYSTIGGO® and ZILBRYSQ®

Accelerated investment behind launches

10 headline results from innovative clinical pipeline

Proprietary and Confidential Property of UCB

1 MAT Q3/2023 IQVIA; 2 Amgen Q4 2023 presentation; 3 UCB books the net sales in Europe;

PsA = Psoriatic Arthritis; nr-axSpA = non-radiographic Axial Spondyloarthritis; EU = Europe; U.S. = United States; LoE = Loss of Exclusivity; bn = billion. UCB - FY 2023 Facts & Figures, February 2024

8

Product Portfolio: Solid foundation & five Growth Drivers

2023 FY Net Sales € 4 867 M1

(-5%;-6% CER)

	KEPPRA®
	14%
CIMZIA®	BRIVIACT®
43%	12%
	VIMPAT®
	9%
	EB
	13%

Neurology € 1 945 M

(-23%;-20% CER)

Immunology € 2 295 M

(+7%; +10% CER)

CIMZIA®

KEPPRA®

BRIVIACT®

VIMPAT®

FINTEPLA®

BIMZELX®

NAYZILAM®

€ M	ACT	CER
			Stronger growth than the anti-TNF market based on
€ 2 087	+0%	+3%	differentiation: treatment option for women of childbearing
age across 6 indications and for rheumatoid arthritis
			patients with high rheumatoid factor levels
€ 636	-13%	-8%	Generic competition in Japan since January 2022.
Diminishing LOE effect
€ 576	+19%	+21%	Continued double-digit growth,
expected peak sales of € 600 M in 2026
€ 394	-65%	-63%	Generic erosion since March 2022 in the U.S., since
September 2022 in Europe. Erosion bottomed out
€ 226			Seizures associated with rare epileptic syndromes - Dravet
+94%	+99%	Syndrome (DS) and Lennox-Gastaut Syndrome (LGS),
			acquired in March 2022, ongoing launches
€ 148			Approved for PSO globally, U.S. launch since mid-Nov. For
>100%	>100%	PsA, AS + nr-axSpA in Europe since May and in Japan since
			December
€ 94	+21%	+24%	Continued double-digit growth

Proprietary and Confidential Property of UCB

			FINTEPLA® 4%
BIMZELX® 2%			NAYZILAM® 2%
EVENITY® 1%	RYSTIGGO®
Europe

EVENITY®

RYSTIGGO®

Established Brands (EB)

€ 60	>100%	>100%	Continued launches in Europe, worldwide net contribution
of € 368 M (+53%) in "other operating income"
€ 19	n/a	n/a	Launched in the U.S. in July 2023
€ 577	-8%	-5%	Includes NEUPRO®, adjusted for product sale -3% -
Impact in H1

1 Net sales include € 50 M designated hedges reclassified to net sales. Before this reclassification: Net sales -9%; ACT = Actual; CER = Constant Exchange Rates; LOE= Loss of Exclusivity; EB = Established Brands; PSO = Psoriasis; PsA = Psoriatic Arthritis; AS = Ankylosing Spondylitis; nr-axSpA = non-radiographic Axial Spondyloarthritis.

UCB - FY 2023 Facts & Figures, February 2024

9

Solid Foundation & Growth Drivers

Growth Past Inflection Point

Growth Drivers

FINTEPLA®

BIMZELX®

EVENITY®

RYSTIGGO®

Growth H2 vs. H1*	FY23 - M	ACT	CER
+22%	€ 226	+94%	+99%	Seizures associated with rare epileptic syndromes - Dravet Syndrome (DS) and
Lennox-Gastaut Syndrome (LGS), acquired in March 2022, ongoing launches
+85%	€ 148	>100%	>100%	Approved for PSO globally, U.S. launch since mid-Nov. For PsA, AS + nr-axSpA
in Europe since May and in Japan since Dec
+50%	€ 60	>100%	>100%	Continued launches in Europe, worldwide net earnings contribution of € 368 M
(+53%) in "other operating income"
n/a	€ 19	n/a	n/a	Launched in the U.S. in July 2023

Confidential Property of UCB

Solid

Foundation

CIMZIA®

KEPPRA®

BRIVIACT®

VIMPAT®

NAYZILAM®

Established Brands (EB)

+5%	€ 2 087	+0%	+3%	Stronger growth than the anti-TNF market based on differentiation: treatment
option for women of childbearing age across 6 indications and for rheumatoid
				arthritis patients with high rheumatoid factor levels
-11%	€ 636	-13%	-8%	Generic competition in Japan since January 2022. Diminishing LOE effect
+11%	€ 576	+19%	+21%	Continued double-digit growth, expected peak sales of € 600 M in 2026
- 7%	€ 394	-65%	-63%	Generic erosion since March 2022 in the U.S., since September 2022 in Europe.
Erosion bottomed out
+24%	€ 94	+21%	+24%	Continued double-digit growth
-14 %	€ 577	-8%	-5%	Includes NEUPRO®, adjusted for product sale -3%
Impact of product sale in H1

Proprietary and

• At Actual Rates; ACT = Actual; CER = Constant Exchange Rates; LOE= Loss of Exclusivity; EB = Established Brands; PSO = Psoriasis; PsA = Psoriatic Arthritis; AS = Ankylosing Spondylitis; nr- axSpA = non-radiographic Axial Spondyloarthritis.

UCB - FY 2023 Facts & Figures, February 2024

10